Eprenetapopt is a small molecule commercialized by Aprea Therapeutics, with a leading Phase II program in Myelodysplastic Syndrome. According to Globaldata, it is involved in 12 clinical trials, of which 8 were completed, 1 is ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Eprenetapopt’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Eprenetapopt is expected to reach an annual total of $57 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Eprenetapopt (PRIMA-1MET) is under development for the treatment of urothelial/bladder cancer, gastric cancer, non small cell lung cancer, platinum sensitive high grade serous ovarian cancer (HGSOC), peritoneal cancer, primary fallopian tube cancer and platinum resistant HGSOC, acute myeloid leukemia, frontline and relapsed/refractory TP53 mutant AML, mantle cell lymphoma and relapsed/refractory TP53 mutant chronic lymphoid leukemia. The drug candidate is administered through intravenous route. APR-246 is a quinuclidinone derivative that targets the Wrap53 gene. It was also under development for the treatment of refractory prostate carcinoma and hematologic malignancies like acute lymphoid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, multiple myeloma, non Hodgkin's lymphoma, Hodgkin's lymphoma, myelofibrosis and metastatic melanoma, small cell lung cancer, breast cancer, adenocarcinoma in gastroesophageal junction cancer, esophageal cancer.
It was also under development for the treatment of non Hodgkin's lymphoma, mantle cell lymphoma, refractory chronic lymphocytic leukemia, relapsed chronic lymphocytic leukemia.
Aprea Therapeutics Overview
Aprea Therapeutics is a biopharmaceutical company that develops cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The company offers products that include APR-246 drugs and therapeutics for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and additional hematologic and solid tumor malignancies. It also has pre-clinical research and development to extend its product development. The company has its additional office in Sweden. Aprea Therapeutics is headquartered in Boston, Massachusetts, the US.
The operating loss of the company was US$37.5 million in FY2021, compared to an operating loss of US$52.8 million in FY2020. The net loss of the company was US$37.1 million in FY2021, compared to a net loss of US$53.5 million in FY2020.
For a complete picture of Eprenetapopt’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.